Literature DB >> 2664882

Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol.

H J Möller1, W Kissling, T Riehl, J Bäuml, U Binz, G Wendt.   

Abstract

1. Today carbamazepine is the most important alternative to neuroleptic drugs for the treatment of manic psychoses. Often carbamazepine is administered as a comedication to a neuroleptic. 2. A doubleblind study with 20 patients suffering from manic or schizomanic psychoses was performed to determine whether carbamazepine and haloperidol in comedication are more effective than haloperidol alone. 3. Under the tested conditions (24 mg haloperidol p.d.) only the smaller amount of additional medication with levomepromazine in the experimental group gave evidence for the antimanic effect of carbamazepine in combination with haloperidol. 4. Especially the patients with pure manic psychoses seem to benefit from carbamazepine as an adjunct to haloperidol.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2664882     DOI: 10.1016/0278-5846(89)90009-2

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

Review 1.  Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice.

Authors:  Robert M Post; Terence A Ketter; Thomas Uhde; James C Ballenger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 2.  Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics?

Authors:  Iria Grande; Eduard Vieta
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

Review 3.  The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure.

Authors:  Per Bech
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy.

Authors:  Yusuke Ogawa; Aran Tajika; Nozomi Takeshima; Yu Hayasaka; Toshi A Furukawa
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 5.  Treatment approaches for acute mania.

Authors:  J C Chou; I Tuma; E A Sweeney
Journal:  Psychiatr Q       Date:  1993

Review 6.  Carbamazepine for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John McGrath
Journal:  Cochrane Database Syst Rev       Date:  2014-05-02

7.  Anticonvulsant drugs in bipolar disorder.

Authors:  H Grunze; S Schlösser; B Amann; J Walden
Journal:  Dialogues Clin Neurosci       Date:  1999-06       Impact factor: 5.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.